Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in ChinaXingxian Luo, Yang Yue, Qixiang Guo et al.|JAMA Network Open|2023Cited by 15
Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in ChinaXingxian Luo, Xiaohong Zhang, Yang Xu et al.|The Lancet Regional Health - Western Pacific|2024Cited by 1
Price trends and affordability of metastatic non–small cell lung cancer drugs in China from 2019 to 2024Xin Du, Yi Zhang, Lin Huang et al.|The Lancet Regional Health - Western Pacific|2025Cited by 0